Viral Vectors for Non-human Primates Market to Reach Over US$ 429.9 Mn by 2034, Driven by Expanding Gene Therapy Pipelines and Advanced Therapeutic Applications: Transparency Market Research

The global viral vectors for non-human primates market was valued at US$ 145.8 Mn in 2023 and is projected to grow at a CAGR of 10.5% from 2024 to 2034, reaching over US$ 429.9 Mn by the end of 2034, according to a recent report by Transparency Market Research.

Analyst Viewpoint

Viral vectors play a pivotal role in advancing gene therapy, vaccine development, and regenerative medicine by enabling precise gene delivery into cells. With non-human primates (NHPs) serving as critical models for preclinical studies due to their genetic proximity to humans, the demand for specialized viral vectors tailored for these studies is expected to witness robust growth.

The landscape comprises a mix of established biotech firms and agile startups, each contributing to innovation. As clinical research pipelines expand-particularly in gene-modified cell therapies such as CAR-T-the global market for viral vectors for NHPs is set for significant expansion.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86344

Viral Vectors for Non-human Primates Market Overview

Viral vectors are engineered viruses used to deliver genetic material into cells for therapeutic or research purposes. These vectors are indispensable in gene therapy, oncolytic treatments, and as vaccine carriers. Their ability to deliver specific DNA or RNA sequences into target cells has led to breakthroughs in treating genetic and chronic diseases.

As of Q1 2024, over 2,093 gene, RNA, and gene-modified cell therapies are under development, including 35 therapies in Phase III, further amplifying the need for robust preclinical models using viral vectors in NHPs.

Key Drivers

Advancements in Gene Therapies and Gene-modified Cell Therapies

Gene and cell therapies now account for 10% of all new drug approvals by the U.S. FDA as of 2023.
CAR-T therapies remain dominant, making up 52% of the gene-modified therapy pipeline.
Increasing need for accurate, translatable preclinical models is accelerating demand for viral vectors in NHP research.

Expanding Therapeutic Applications of Viral Vectors

Viral vectors, especially AAVs and lentiviruses, are being explored beyond rare disease treatment to include oncology, infectious diseases, and neurological disorders.
The U.S. FDA has approved multiple viral-vector-based therapies; over 120 viral-vector products are in Phase II trials, signaling a growing pipeline.

Regional Outlook

North America dominated the market in 2023, accounting for 48.3% of global share. The U.S. leads in biotech innovation, with a high concentration of R&D institutions, biotech firms, and CGT-focused labs.

In March 2022, researchers at Mass Eye and Ear (Harvard Medical School) demonstrated successful inner-ear gene delivery using Anc80L65 in NHPs-a milestone that opens the door to clinical applications for hearing and balance disorders.

Competitive Landscape

The market features a balanced mix of large-scale manufacturers and agile innovators. Companies are pursuing strategic collaborations, acquisitions, and facility expansions to address growing demand.

Key Companies Profiled

Lonza
Thermo Fisher Scientific Inc.
Revvity
VectorBuilder Inc.
Creative Biolabs
Takara Bio Inc.
Merck KGaA
Andelyn Biosciences
Biovian Oy
Genezen

Recent Developments

May 2024 - Merck KGaA acquired Mirus Bio for US$ 600 Mn, strengthening its transfection reagent portfolio.
June 2023 - Takara Bio Inc. partnered with Gap Junction Therapeutics to develop AAV vector therapy for GJB2-linked hearing loss.
October 2022 - Lonza expanded CGT development labs in the U.S. and Netherlands, enhancing viral vector process capabilities.

Market Segmentation

By Vector Type

Adenoviral Vectors
Adeno-associated Vectors
Retroviral Vectors
Lentiviral Vectors
Other Vectors (e.g., Baculoviral)

By Type of Non-human Primates

Marmosets
Rhesus Macaques
Cynomolgus Monkeys
Others (e.g., Chimpanzees, Capuchins)

By Application

Gene Therapy
Vaccine Research

By Therapeutic Area

Genetic Disorders
Infectious Diseases
Oncological Disorders
Others

By End-user

Pharmaceutical & Biotechnology Companies
Academic & Research Institutions

Buy this Premium Research Report:

https://www.transparencymarketresearch.com/checkout.php?rep_id=86344<ype=S

Explore Latest Research Reports by Transparency Market Research:

Respiratory Monitoring Devices Market- https://www.transparencymarketresearch.com/respiratory-monitoring-devices.html

Cell Culture Market- https://www.transparencymarketresearch.com/cell-culture-market.html

Equine Healthcare Market- https://www.transparencymarketresearch.com/equine-healthcare-market.html

Elderly and Disabled Assistive Devices Market- https://www.transparencymarketresearch.com/elderly-disabled-assistive-devices.html

Breast Pumps Market- https://www.transparencymarketresearch.com/breast-pumps-market.html

Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.